https://www.selleckchem.com/pr....oducts/fumarate-hydr
ients with progressive disease by both PERICST 1.0 and PSA response criteria demonstrated significantly worse OS (24-month OS 0%, 12-month OS 31% ± 14%) compared to patients with progressive disease by either response criteria. Conclusion PERCIST 1.0 may provide significant prognostic information for patients with mCRPC undergoing systemic chemotherapy, particularly when incorporated with PSA treatment response criteria. © The author(s).Rationale Of the regulatory microRNAs expressed in the wounded skin, microRNA-21 (miR
Like
Comment
Share
